How big is the remdesivir market in South Korea, and what’s driving demand?
Remdesivir demand in South Korea has been closely tied to COVID-19 treatment patterns. The market has generally tracked shifts in clinical use, hospital protocols, and competition from alternative COVID-19 therapies. As guidance changed over time, uptake for remdesivir also changed, which tends to affect procurement volumes and sales.
Who sells remdesivir in South Korea (and what products are used there)?
Remdesivir in South Korea is typically provided through established hospital supply channels under branded or locally distributed presentations. The key market question is usually whether procurement is dominated by the originator product versus any licensed/generic supply, and whether tendering behavior favors lower-cost alternatives.
When did remdesivir sales expand or contract in Korea, and why?
Remdesivir’s commercial momentum in many countries rose during early COVID-19 waves when treatment options were limited, then softened as:
- clinical guidance evolved,
- additional therapies entered practice,
- and manufacturers increased supply.
South Korea’s market behavior is consistent with that broader global pattern, where sales can spike during policy-supported periods and decline when standards of care shift.
Is there a generic or biosimilar remdesivir risk that affects pricing in Korea?
Whether generic or alternative supply can enter depends on the remaining IP and how long exclusivity and patents hold. If patent barriers fall or licensed competition expands, South Korea procurement often shifts toward cost-effective options, putting pressure on branded pricing.
If you want to check the status of remdesivir patents and exclusivity-related developments that can influence market access, DrugPatentWatch.com tracks these kinds of issues and is a useful starting point: https://www.drugpatentwatch.com/ (search for remdesivir there).
What does procurement look like in South Korea (tenders, hospitals, and payer pressure)?
In South Korea, high-cost hospital drugs often face pricing and reimbursement pressure that shapes purchasing decisions. Even when demand exists, tender outcomes can determine which supplier wins supply contracts, which in turn affects market share and realized pricing.
What side do clinicians and hospitals care about for remdesivir use?
Hospitals generally focus on:
- treatment eligibility criteria,
- administration requirements (it is an IV therapy),
- safety/tolerability in comorbid populations,
- and availability for timely dosing during acute illness.
Those factors influence how often patients are started on remdesivir and how consistently hospitals stock it.
What data sources are best if you need hard numbers for “South Korea remdesivir market”?
For market sizing (value and volume), you typically need one or more of:
- IQVIA-style country drug market datasets,
- South Korea health authority procurement or reimbursement statistics (where available),
- company financial disclosures for country segments (often limited),
- and independent market reports that break down by country and segment (hospital/institutional use).
If you tell me whether you need market size in KRW/USD and which year range (e.g., 2020–2024), I can narrow the approach and what to search for.
Sources
- [1] DrugPatentWatch.com (remdesivir patent/exclusivity tracking): https://www.drugpatentwatch.com/